M&A Deal Summary

ACADIA Acquires CerSci Therapeutics

On August 25, 2020, ACADIA acquired life science company CerSci Therapeutics for 53M USD

Acquisition Highlights
  • This is ACADIA’s 1st transaction in the Life Science sector.
  • This is ACADIA’s largest (disclosed) transaction.
  • This is ACADIA’s 1st transaction in the United States.
  • This is ACADIA’s 1st transaction in Texas.

M&A Deal Summary
Date 2020-08-25
Target CerSci Therapeutics
Sector Life Science
Buyer(s) ACADIA
Deal Type Add-on Acquisition
Deal Value 53M USD
Advisor(s) Evercore Group (Financial)
Skadden, Arps, Slate, Meagher & Flom (Legal)

Target

CerSci Therapeutics

Dallas, Texas, United States
CerSci Therapeutics, Inc. is a clinical-stage biotechnology company with worldwide rights to a portfolio of novel compounds for neurological conditions, including non-opioid therapies for acute and chronic pain. CerSci Therapeutics was founded in 2015 and is based in Dallas, Texas.

Search 198,242 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

ACADIA

San Diego, California, United States
Category Company
Founded 1993
Sector Life Science
Employees610
Revenue 726M USD (2023)
DESCRIPTION

ACADIA is a biopharmaceutical company focused on the development and commercialization of innovative medicines to address unmet medical needs in central nervous system disorders. ACADIA has developed and commercialized the first and only medicine approved for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. ACADIA was incorporated in 1993 and is based in San Diego, California.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Texas) 1 of 1
Country (United States) 1 of 1
Year (2020) 1 of 1
Size (of disclosed) 1 of 1
Mergr

Product

Company

Legal